CANCER FUND is a community of impact investors. We invest in early-stage companies advancing cancer innovations beyond research and through development to improve outcomes for patients, survivors, and previvors. CANCER FUND makes investing in cancer innovation fast, easy, and affordable. Learn more at www.CancerFund.comSECURITIES DISCLAIMER: Cancer Fund private placement offerings are made only to eligible investors that can bear the economic risk of their investment for an indefinite period of time and can afford to sustain a total loss of their total investment. The information set forth in this communication does not constitute either an offer to sell or an offer to purchase securities. No investor funds will be accepted absent the execution and delivery by each investor of final definitive legal agreements.

CANCER FUND invested in NXgenPort because of its potential to revolutionize cancer care through innovative technology. By integrating real-time remote monitoring with a proven implantable port design, NXgenPort aims to address critical gaps in managing chemotherapy for patients and their physicians. Detecting life-threatening conditions early could reduce hospitalizations, and improve treatment outcomes aligns with CANCER FUND’s mission to advance impactful innovations.

CANCER FUND invested in Veana Therapeutics to support the development of novel treatments for breast and other cancers. Veana is a clinical-stage biopharmaceutical company currently examining the use of its lead compound, VT-101, in a clinical trial of women with intractable breast cancer. VT-101 works by destabilizing mitochondria (the powerhouse of cells), thereby inducing both apoptotic and immunogenic cell death – potentially killing cancer cells in a selective manner. We believe Veana’s promising early results if validated in expanded testing, could help save lives and improve the quality of life for patients in treatment.

Early data show that Avesta76’s targeted therapeutics offer promise for multiple cancers of interest to our investor community, including chemo-resistant ovarian cancer, breast cancer (specifically Triple Negative Breast Cancer), and colorectal cancer among others. Forty years and three generations of the same family have culminated in a novel targeted therapeutic showing promising early animal testing data indicating efficacy in both tumor prevention and regression with no indication of the cytotoxic effects associated with chemotherapies. We believe that it may offer a new therapeutic alternative for patients who have developed chemo-resistance to current treatments, saving lives and improving patient survival.

Ovarian cancer is among the most deadly cancer types. Diagnosis is commonly made at later stages where treatment options are limited, leading to a 5-year survival rate of only 28%. AOA’s innovative test offers the promise of earlier detection of Ovarian cancer when symptoms first present, and early detection saves lives. As an impact investment, CANCER FUND sees AOA Dx as a potential breakthrough in improving early cancer detection and opening up more effective treatment options for patients.

NearWave holds promise as a potential breakthrough improvement in breast cancer diagnosis and treatment. Their novel handheld clinical device uses imaging technology to monitor patient response to neoadjuvant chemotherapy, which is the first line of treatment in stage IIB breast cancer patients. The system’s ease of use in the clinic and relative affordability, coupled with potentially high detection specificity and sensitivity, may also expand access to effective diagnostic care in rural and low-income areas.

Reglagene is creating new drug treatments to effectively reach and treat the brain. Their leading product, RGN6024, is a major advancement in treating brain cancers. This drug works by targeting a key process in cancer cells, making it a powerful weapon against the disease. It's taken orally, easy on the body, and has an exceptional ability to reach the brain. This makes it a hopeful option for people with primary brain cancer and those with brain-related complications from breast and lung cancer. In the next stage of development for RGN6024, Reglagene is preparing to submit it for FDA review and aiming to start clinical trials by early 2025.

CXO provides advisory, governance, and interim management to venture capital funds and ventures commercializing technologies and solutions for heath, wellness, and well-being. CXO’s partners are proven venture capitalists, entrepreneurs, and executives applying their experience to help clients through ideation, innovation, incubation, and acceleration stages.